Parkinsons Disease Home > Sinemet CR

Sinemet CR is a prescription medication licensed to treat Parkinson's disease and Parkinson-like symptoms caused by certain conditions. It helps to increase the levels of dopamine in the brain, which may be responsible for many of the symptoms of Parkinson's disease. The tablets are specially designed to slowly release the medication to prevent fluctuations in the level of carbidopa and levodopa in the blood.

What Is Sinemet CR?

Sinemet® CR (carbidopa-levodopa CR) is a prescription medication most frequently used to treat Parkinson's disease. This medication is also approved to treat parkinsonism (Parkinson-like symptoms) due to encephalitis (inflammation or infection of the brain), manganese poisoning, or carbon monoxide poisoning. It is specially designed to slowly release the medication over four to six hours, which helps to prevent fluctuations in the level of carbidopa and levodopa in the blood.
 
(Click Sinemet CR Uses for more information on this topic, including possible off-label uses.)
 

Who Makes Sinemet CR?

Sinemet CR is made by Mylan Pharmaceuticals, Inc., for Merck & Co., Inc.
 

How Does It Work?

Sinemet CR contains two different active ingredients: levodopa and carbidopa. The levodopa is the "real" ingredient in Sinemet CR that works for Parkinson's disease. The carbidopa does not have any direct effects on Parkinson's disease when used alone, but it does help to make the levodopa more effective.
 
Dopamine deficiency (caused by a loss of dopamine-producing cells) in certain parts of the brain may be responsible for many of the symptoms of Parkinson's disease. Although it would make sense to give dopamine to help treat Parkinson's, this does not work, as dopamine cannot cross the blood-brain barrier to reach the brain. Levodopa is a precursor of dopamine, which means that the body can use it to make dopamine. Unlike dopamine, levodopa crosses the blood-brain barrier.
 
Levodopa is almost always given in combination with carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain, preventing or diminishing some of the side effects that often accompany levodopa therapy. Carbidopa also reduces the amount of levodopa needed for Parkinson's disease treatment.
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation
Advertisement


Topics & Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2017 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.